Galuppo Roberto, McCall Angie, Gedaly Roberto
Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536-0293, USA.
Int J Hepatol. 2013;2013:419302. doi: 10.1155/2013/419302. Epub 2013 Dec 19.
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver accounting for 7% of all cancers worldwide. Most cases of HCC develop within an established background of chronic liver disease. For that reason, liver resection is only possible in selected patients. Liver transplantation has become the treatment of choice in patients with HCC, end-stage liver disease, and significant portal hypertension. Shortage of organ donors has resulted in overall increase of waiting list time with increased risk of dropout due to tumor progression. Neoadjuvant therapies have emerged as an alternative to control tumor growth in patients while waiting. The aim of this study is to review the literature on the role of bridging therapy and downstaging prior to liver transplantation in patients with HCC. We are also presenting our single-center experience of 96 patients undergoing transplantation for HCC with and without bridging therapy.
肝细胞癌（HCC）是最常见的原发性肝脏恶性肿瘤，占全球所有癌症的7%。大多数HCC病例在慢性肝病的既定背景下发生。因此，肝切除术仅适用于选定的患者。肝移植已成为HCC、终末期肝病和严重门静脉高压患者的首选治疗方法。器官供体短缺导致等待名单时间总体增加，因肿瘤进展而退出的风险增加。新辅助治疗已成为在患者等待期间控制肿瘤生长的一种替代方法。本研究的目的是回顾关于HCC患者肝移植前桥接治疗和降期作用的文献。我们还介绍了我们单中心96例接受或未接受桥接治疗的HCC移植患者的经验。
